Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases

被引：77

作者：

Steinacker, P

Mollenhauer, B

Bibl, M

Cepek, L

Esselmann, H

Brechlin, P

Lewczuk, P

Poser, S

Kretzschmar, HA

Wiltfang, J

Trenkwalder, C

Otto, M

机构：

[1] Univ Hosp, Dept Neurol, D-37075 Gottingen, Germany

[2] Univ Hosp, Dept Psychiat, Gottingen, Germany

[3] Univ Hosp, Dept Psychiat, Erlangen, Germany

[4] Univ Munich, Dept Neuropathol, Munich, Germany

[5] Paracelsus Elena Hosp, Kassel, Germany

来源：

NEUROSCIENCE LETTERS | 2004年 / 370卷 / 01期

关键词：

dementia; neurodegeneration; heart-type fatty acid binding protein; Creutzfeldt-Jakob disease; dementia with Lewy-bodies; Alzheimer's disease; biomarker;

D O I：

10.1016/j.neulet.2004.07.061

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The diagnosis of neurodegenerative diseases with demential requires several different test approaches and often remains uncertain. Using a proteomic approach it was shown in nine patients that heart fatty acid binding protein (H-FABP) might be a biomarker for Creutzfeldt-Jakob disease (CJD). The aim of our study was to evaluate whether H-FABP is a biomarker for the differential diagnosis of dementias. Therefore we measured H-FABP in cerebrospinal fluid (CSF) and serum of patients having CJD, dementia with Lewy-bodies (DLB), Alzheimer's disease (AD) and in non-demented control (NDC) patients. H-FABP levels in CSF and serum of CJD patients are increased compared to non-demented controls. Levels of H-FABP were significantly higher in CJD patients compared to AD and DLB in CSF. However, discrimination between CJD and AD was not possible in serum. Interestingly, highest levels of H-FABP were found in serum of DLB patients. Our results suggest that H-FABP might be a useful biomarker for the differentiation between the dementias examined if levels in CSF and serum are determined in parallel. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：36 / 39

页数：4

共 21 条

[1] Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].

Andreasen, N ;

Vanmechelen, E ;

Van de Voorde, A ;

Davidsson, P ;

Hesse, C ;

Tarvonen, S ;

Räihä, I ;

Sourander, L ;

Winblad, B ;

Blennow, K .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305

[2] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[3]

[Anonymous], 1998, Wkly Epidemiol Rec, V73, P361

[4] PROTEIN SIZE AND CEREBROSPINAL-FLUID COMPOSITION [J].

FELGENHAUER, K .

KLINISCHE WOCHENSCHRIFT, 1974, 52 (24) :1158-1164

[5] Fatty acid-binding protein and the early detection of acute myocardial infarction [J].

Glatz, JFC ;

van der Vusse, GJ ;

Simoons, ML ;

Kragten, JA ;

van Dieijen-Visser, MP ;

Hermens, WT .

CLINICA CHIMICA ACTA, 1998, 272 (01) :87-92

[6] A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease [J].

Guillaume, E ;

Zimmermann, C ;

Burkhard, PR ;

Hochstrasser, DF ;

Sanchez, JC .

PROTEOMICS, 2003, 3 (08) :1495-1499

[7] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].

Hulstaert, F ;

Blennow, K ;

Ivanoiu, A ;

Schoonderwaldt, HC ;

Riemenschneider, M ;

De Deyn, PP ;

Bancher, C ;

Cras, P ;

Wiltfang, J ;

Mehta, PD ;

Iqbal, K ;

Pottel, H ;

Vanmechelen, E ;

Vanderstichele, H .

NEUROLOGY, 1999, 52 (08) :1555-1562

[8] Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop [J].

McKeith, IG ;

Galasko, D ;

Kosaka, K ;

Perry, EK ;

Dickson, DW ;

Hansen, LA ;

Salmon, DP ;

Lowe, J ;

MIrra, SS ;

Byrne, EJ ;

Lennox, G ;

Quinn, NP ;

Edwardson, JA ;

Ince, PG ;

Bergeron, C ;

Burns, A ;

Miller, BL ;

Lovestone, S ;

Collerton, D ;

Jansen, ENH ;

Ballard, C ;

deVos, RAI ;

Wilcock, GK ;

Jellinger, KA ;

Perry, RH .

NEUROLOGY, 1996, 47 (05) :1113-1124

[9]

MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939

[10] REDUCTION OF BETA-AMYLOID PEPTIDE(42), IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH ALZHEIMERS-DISEASE [J].

MOTTER, R ;

VIGOPELFREY, C ;

KHOLODENKO, D ;

BARBOUR, R ;

JOHNSONWOOD, K ;

GALASKO, D ;

CHANG, L ;

MILLER, B ;

CLARK, C ;

GREEN, R ;

OLSON, D ;

SOUTHWICK, P ;

WOLFERT, R ;

MUNROE, B ;

LIEBERBURG, I ;

SEUBERT, P ;

SCHENK, D .

ANNALS OF NEUROLOGY, 1995, 38 (04) :643-648

← 1 2 3 →